Lumida
/AVTX
⌘K
AVTX

AVTX

AVTX
$19.37USD+8.33%+1.49 today

MARKET CAP

1.0B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $19

52W RANGE

$5
$24

AI Summary

Stalk
Buy NowMedium

AVTX remains in a Stage 2 advancing phase with clear higher highs and higher lows, supported by an active Lockout Rally pattern. The medium-term bias is bullish, and a recent pullback into the rising 9/21 EMAs offers a preferential entry point near the prior breakout zone. With a speculative strategy focus, execution on a successful hold of EMAs and breakout support aligns with continuation participation. Key risks include potential supply at multi-month highs and any breakdown below dynamic support.

  • Phase 2 hidradenitis trial showed significant improvement metrics vs. baseline.
  • Analyst estimate upgrades reflect strong growth outlook.
  • Negative profitability trends raise doubts about cash-flow breakeven.
Full analysis →
Insider Trades25 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 30, 2026SellAVTXMittie DoyleChief Medical Officer9,308$15.44$1.0B-20.19%+302.70%$143.8K+0.00%10b5-1Buy Now
Jun 23, 2026SellAVTXMittie DoyleChief Medical Officer2,900$13.02$1.0B-20.19%+302.70%$37.8K+0.00%10b5-1Buy Now
Jun 10, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer138$13.10$1.0B-20.19%+302.70%$1.8K-0.34%Buy Now
Jun 10, 2026SellAVTXJennifer RileyChief Strategy Officer588$13.10$1.0B-20.19%+302.70%$7.7K-1.46%Buy Now
Jun 10, 2026SellAVTXPaul VarkiChief Legal Officer1,081$13.10$1.0B-20.19%+302.70%$14.2K-3.21%Buy Now
Jun 10, 2026SellAVTXMittie DoyleChief Medical Officer1,084$13.10$1.0B-20.19%+302.70%$14.2K-2.05%Buy Now
May 28, 2026SellAVTXMittie DoyleChief Medical Officer1,358$12.02$1.0B-20.19%+302.70%$16.3K+0.00%10b5-1Buy Now
May 15, 2026SellAVTXMittie DoyleChief Medical Officer6,000$15.71$1.0B-20.19%+302.70%$94.2K+0.00%10b5-1Buy Now
May 7, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer37,212$17.00$1.0B-20.19%+302.70%$632.6K+0.00%10b5-1Buy Now
May 6, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer94,000$14.11$1.0B-20.19%+302.70%$1.3M+0.00%10b5-1Buy Now
May 6, 2026SellAVTXPaul VarkiChief Legal Officer150,126$16.35$1.0B-20.19%+302.70%$2.5M+0.00%10b5-1Buy Now
May 5, 2026SellAVTXMittie DoyleChief Medical Officer216,468$16.00$1.0B-20.19%+302.70%$3.5M+0.00%10b5-1Buy Now
Apr 29, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer16,915$13.16$1.0B-20.19%+302.70%$222.6K-64.52%10b5-1Buy Now
Apr 6, 2026SellAVTXMittie DoyleChief Medical Officer7,940$15.33$1.0B-20.19%+302.70%$121.7K+0.00%10b5-1Buy Now
Apr 1, 2026SellAVTXMittie DoyleChief Medical Officer1,358$12.02$1.0B-20.19%+302.70%$16.3K+0.00%10b5-1Buy Now
Apr 1, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer15,959$16.96$1.0B-20.19%+302.70%$270.6K-14.44%10b5-1Buy Now
Mar 28, 2026SellAVTXChristopher Ryan SullivanChief Financial Officer8,241$13.89$1.0B-20.19%+302.70%$114.5K-12.54%Buy Now
Mar 28, 2026SellAVTXGarry Arthur NeilChief Executive Officer21,892$13.89$1.0B-20.19%+302.70%$304.1K-12.38%Buy Now
Mar 16, 2026SellAVTXMittie DoyleChief Medical Officer50,984$13.86$1.0B-20.19%+302.70%$706.5K+0.00%Buy Now
Dec 10, 2025SellAVTXChristopher Ryan SullivanChief Financial Officer155$4.10$1.0B-20.19%+302.70%$635.5-0.89%Buy Now
Dec 10, 2025SellAVTXJennifer RileyChief Strategy Officer637$4.10$1.0B-20.19%+302.70%$2.6K-19.35%Buy Now
Dec 10, 2025SellAVTXMittie DoyleChief Medical Officer1,013$4.10$1.0B-20.19%+302.70%$4.2K-21.86%Buy Now
Dec 10, 2025SellAVTXPaul VarkiChief Legal Officer1,016$4.10$1.0B-20.19%+302.70%$4.2K-21.85%Buy Now
Mar 28, 2025SellAVTXChristopher Ryan SullivanChief Financial Officer7,285$8.46$1.0B-20.19%+302.70%$61.6K-10.03%Buy Now
Mar 28, 2025SellAVTXGarry Arthur NeilChief Executive Officer17,787$8.46$1.0B-20.19%+302.70%$150.5K-9.14%Buy Now